Literature DB >> 14595745

Pathogenetic mechanisms in usual interstitial pneumonia/idiopathic pulmonary fibrosis.

Eric S White1, Michael H Lazar, Victor J Thannickal.   

Abstract

Idiopathic pulmonary fibrosis (IPF) is a progressive, usually fatal, form of interstitial lung disease characterized by failure of alveolar re-epithelialization, persistence of fibroblasts/myofibroblasts, deposition of extracellular matrix, and distortion of lung architecture which ultimately results in respiratory failure. Clinical IPF is associated with a histopathological pattern of usual interstitial pneumonia (UIP) on surgical lung biopsy. Therapy for this disease with glucocorticoids and other immunomodulatory agents is largely ineffective and recent trials of newer anti-fibrotic agents have been disappointing. While the inciting event(s) leading to the initiation of scar formation in UIP remain unknown, recent advances in our understanding of the mechanisms underlying both normal and aberrant wound healing have shed some light on pathogenetic mechanisms that may play significant roles in this disease. Unlike other fibrotic diseases of the lung, such as those associated with collagen vascular disease, occupational exposure, or chemotherapeutic agents, UIP is not associated with a significant inflammatory response; rather, dysregulated epithelial-mesenchymal interactions predominate. Identification of pathways crucial to fibrogenesis might offer potentially novel therapeutic targets to slow or halt the progression of IPF. This review focuses on evolving concepts of cellular and molecular mechanisms in the pathogenesis of UIP/IPF. Copyright 2003 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2003        PMID: 14595745      PMCID: PMC2810622          DOI: 10.1002/path.1446

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  143 in total

Review 1.  American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001.

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  2002-01-15       Impact factor: 21.405

Review 2.  Normal scarring: importance of myofibroblasts.

Authors:  Dione Lorena; Kozue Uchio; Andréa Monte Alto Costa; Alexis Desmoulière
Journal:  Wound Repair Regen       Date:  2002 Mar-Apr       Impact factor: 3.617

3.  The relationship between individual histologic features and disease progression in idiopathic pulmonary fibrosis.

Authors:  Andrew G Nicholson; Laura G Fulford; Thomas V Colby; Roland M du Bois; David M Hansell; Athol U Wells
Journal:  Am J Respir Crit Care Med       Date:  2002-07-15       Impact factor: 21.405

4.  Heterozygosity for a surfactant protein C gene mutation associated with usual interstitial pneumonitis and cellular nonspecific interstitial pneumonitis in one kindred.

Authors:  Alan Q Thomas; Kirk Lane; John Phillips; Melissa Prince; Cheryl Markin; Marcy Speer; David A Schwartz; Radhika Gaddipati; Annis Marney; Joyce Johnson; Richard Roberts; Jonathan Haines; Mildred Stahlman; James E Loyd
Journal:  Am J Respir Crit Care Med       Date:  2002-05-01       Impact factor: 21.405

5.  MAP kinase activation and apoptosis in lung tissues from patients with idiopathic pulmonary fibrosis.

Authors:  Koichiro Yoshida; Kazuyoshi Kuwano; Naoki Hagimoto; Kentaro Watanabe; Tokuji Matsuba; Masaki Fujita; Ichiro Inoshima; Nobuyuki Hara
Journal:  J Pathol       Date:  2002-11       Impact factor: 7.996

6.  Inducible lung-specific urokinase expression reduces fibrosis and mortality after lung injury in mice.

Authors:  Thomas H Sisson; Kerstin E Hanson; Natalya Subbotina; Anjali Patwardhan; Noboru Hattori; Richard H Simon
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2002-11       Impact factor: 5.464

7.  Nationwide prevalence of sporadic and familial idiopathic pulmonary fibrosis: evidence of founder effect among multiplex families in Finland.

Authors:  U Hodgson; T Laitinen; P Tukiainen
Journal:  Thorax       Date:  2002-04       Impact factor: 9.139

8.  Prostaglandin E2 synthesis and suppression of fibroblast proliferation by alveolar epithelial cells is cyclooxygenase-2-dependent.

Authors:  Vibha Lama; Bethany B Moore; Paul Christensen; Galen B Toews; Marc Peters-Golden
Journal:  Am J Respir Cell Mol Biol       Date:  2002-12       Impact factor: 6.914

9.  Future research directions in idiopathic pulmonary fibrosis: summary of a National Heart, Lung, and Blood Institute working group.

Authors:  Ronald G Crystal; Peter B Bitterman; Brooke Mossman; Marvin I Schwarz; Dean Sheppard; Laura Almasy; Harold A Chapman; Scott L Friedman; Talmadge E King; Leslie A Leinwand; Lance Liotta; George R Martin; David A Schwartz; Gregory S Schultz; Carston R Wagner; Robert A Musson
Journal:  Am J Respir Crit Care Med       Date:  2002-07-15       Impact factor: 21.405

10.  A rearranged form of Epstein-Barr virus DNA is associated with idiopathic pulmonary fibrosis.

Authors:  Brian G Kelly; She S Lok; Philip S Hasleton; Jim J Egan; James P Stewart
Journal:  Am J Respir Crit Care Med       Date:  2002-08-15       Impact factor: 21.405

View more
  76 in total

1.  Oxidative damage and TGF-β differentially induce lung epithelial cell sonic hedgehog and tenascin-C expression: implications for the regulation of lung remodelling in idiopathic interstitial lung disease.

Authors:  Paul M Fitch; Sarah E M Howie; William A H Wallace
Journal:  Int J Exp Pathol       Date:  2010-10-29       Impact factor: 1.925

2.  Enhanced myofibroblastic differentiation and survival in Thy-1(-) lung fibroblasts.

Authors:  Yan Y Sanders; Pallavi Kumbla; James S Hagood
Journal:  Am J Respir Cell Mol Biol       Date:  2006-09-07       Impact factor: 6.914

3.  Regional fibroblast heterogeneity in the lung: implications for remodeling.

Authors:  Chakradhar Kotaru; Kathryn J Schoonover; John B Trudeau; Mai-Lan Huynh; XiuXia Zhou; Haizhen Hu; Sally E Wenzel
Journal:  Am J Respir Crit Care Med       Date:  2006-03-16       Impact factor: 21.405

4.  Integration and Evaluation of Clinical Decision Support Systems for Diagnosis Idopathics Pulmonary Fibrosis (IPF).

Authors:  Yunhee Lee; Youngmoon Chae; Sungwan Jeon
Journal:  Healthc Inform Res       Date:  2010-12-31

5.  Inhibition of transglutaminase 2, a novel target for pulmonary fibrosis, by two small electrophilic molecules.

Authors:  Keith C Olsen; Amali P Epa; Ajit A Kulkarni; R Matthew Kottmann; Claire E McCarthy; Gail V Johnson; Thomas H Thatcher; Richard P Phipps; Patricia J Sime
Journal:  Am J Respir Cell Mol Biol       Date:  2014-04       Impact factor: 6.914

6.  Protein Tyrosine Phosphatase-N13 Promotes Myofibroblast Resistance to Apoptosis in Idiopathic Pulmonary Fibrosis.

Authors:  Alison Bamberg; Elizabeth F Redente; Steve D Groshong; Rubin M Tuder; Carlyne D Cool; Rebecca C Keith; Benjamin L Edelman; Bart P Black; Gregory P Cosgrove; Murry W Wynes; Douglas Curran-Everett; Stijn De Langhe; Luis A Ortiz; Andrew Thorburn; David W H Riches
Journal:  Am J Respir Crit Care Med       Date:  2018-10-01       Impact factor: 21.405

7.  Regulation of myofibroblast differentiation and bleomycin-induced pulmonary fibrosis by adrenomedullin.

Authors:  Jacob Kach; Nathan Sandbo; Nan Sethakorn; Jesse Williams; Eleanor B Reed; Jennifer La; Xinyong Tian; Susan D Brain; Kavitha Rajendran; Ramaswamy Krishnan; Anne I Sperling; Konstantin Birukov; Nickolai O Dulin
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2013-04-12       Impact factor: 5.464

8.  Thalidomide has a therapeutic effect on interstitial lung fibrosis: evidence from in vitro and in vivo studies.

Authors:  L Zhao; K Xiao; H Wang; Z Wang; L Sun; F Zhang; X Zhang; F Tang; W He
Journal:  Clin Exp Immunol       Date:  2009-08       Impact factor: 4.330

9.  Salidroside protects against bleomycin-induced pulmonary fibrosis: activation of Nrf2-antioxidant signaling, and inhibition of NF-κB and TGF-β1/Smad-2/-3 pathways.

Authors:  Haiying Tang; Lili Gao; Jingwei Mao; Huanyu He; Jia Liu; Xin Cai; Hongli Lin; Taihua Wu
Journal:  Cell Stress Chaperones       Date:  2015-11-17       Impact factor: 3.667

10.  Centrifugal migration of mesenchymal cells in embryonic lung.

Authors:  Lin Shan; Meera Subramaniam; Rodica L Emanuel; Simone Degan; Pamela Johnston; Denise Tefft; David Warburton; Mary E Sunday
Journal:  Dev Dyn       Date:  2008-03       Impact factor: 3.780

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.